Equibles does not estimate personal net worth.
Get an email with a short summary when Ultragenyx Pharmaceutical Inc. publishes a filing, an earnings call transcript or a press release.
Get RARE alertsErik Harris was last confirmed as Board Member at Denali Therapeutics Inc. (DNLI) in a filing dated April 17, 2025. The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $4,045,072 for Erik Harris in fiscal 2025, including a base salary of $619,692. Disclosed compensation is on record for 8 fiscal years. Erik Harris has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Ultragenyx Pharmaceutical Inc. on November 3, 2026. Ultragenyx Pharmaceutical Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ultragenyx Pharmaceutical Inc. includes Emil D. Kakkis (CEO and Board Member), Emil Kakkis (CEO and Board Member), Howard Horn (CFO) and 7 others.
“It has been an exciting few months for our commercial team, with the approvals of Genglycos in August and Fayuvie in September, bringing our fifth and sixth approved medicines to patients and our first two gene therapies.”
“First, I'd like to acknowledge what a rare privilege it is to have the opportunity to launch two drugs in a month, impacting the lives of patients with significant unmet needs.”
“We feel confident we have a sufficient number of QTCs under contract now and expect that to expand very quickly now following approval and with the potential to double by the end of the year.”
“As Amo mentioned, the underlying business remains strong, and we are well positioned to capitalize on the potential upcoming launches. Howard will share details, but we remain fully confident in our 2026 revenue guidance.”
“I want to begin by expanding a bit on Amos' earlier comments about the strength and durability of our existing commercial business, which continues to deliver strong performance across markets and products.”
Proxy statement
Start not stated–present
Last confirmed March 27, 2026
2022-01-01–2025-04-17
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
Biotechnology · Healthcare
Board Member
Since 2022-01-01, last confirmed 2025-04-17
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $619,692 | $4,045,072 |
| 2024 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $604,231 | $4,295,813 |
| 2023 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $585,969 | $4,068,567 |
| 2022 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $566,331 | $3,748,555 |
| 2021 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $543,846 | $3,317,210 |
| 2020 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $501,247 | $2,224,299 |
| 2019 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $418,077 | $2,273,392 |
| 2018 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Commercial Officer and Executive Vice President | $356,154 | $641,070 |
